QVQ
- – Performs Contract Research for industrial partners and academic research groups according to either Service- or Collaboration Agreements.
- – Provides extensive expertise in each step of VHH-development, ranging from immunization, selection and screening to GMP production.
- – Sells high quality VHHs directed against various bacteria, fungi, viruses and human targets in cancer, age related diseases and infectious diseases.
Latest from us
QVQ Holding b.v. as partner of a larger consortium and in collaboration with its daughter company Orthros TR b.v. -has received a substantial grant from EU and Op Oost [NL] to develop Read more
QVQ Holding b.v. and Hans Knoll Institute in Jena [Germany] have filed a patent to combat Candidiasis with lama antibodies [VHH]. Candidiasis is caused by Candida albicans and infection with C. albicans Read more
We are pleased to announce that QVQ holding has joined the Biotech Investissement group and is now a sister company of RD-Biotech SAS, Diaclone SAS and SynAbs SA (www.mabexperts.com). RD-Biotech is a Read more
Case study HIV
